en · de · es · pt
lab-handbook.peptides6908.com › News › Mechanism And Safety Research — Field Notes

Mechanism And Safety Research — Field Notes

By Editorial Desk · published 2026-03-02 · last reviewed 2026-04-17 · News

preclinical models is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-04-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Safety Research

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.

Background and Research Context

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδNuclear receptor; not androgen receptor
Studied indicationsDyslipidemia; obesity; diabetesEarly clinical research; development discontinued
Rodent toxicityTumor formation in multiple tissuesDose-dependent findings in some studies
Human approvalNoneNo approved therapeutic use
Typical analytical methodLC-MS/MSUsed for identity and quantification

Regulatory Status and Detection Context

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Related pages on this site

Regulation and Detection

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Mechanism and Research Context

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

Reference notes

The vocal cords, also known as vocal folds, are folds of throat tissues that are key in creating sounds through vocalization. The length of the vocal cords affects the pitch of voice, similar to a stringed musical instrument. Open when breathing and vibrating for speech or singing, the folds are controlled via the recurrent laryngeal branch of the vagus nerve. They are composed of twin infoldings of mucous membrane stretched horizontally, from back to front, across the larynx. They vibrate, modulating the flow of air being expelled from the lungs during phonation. The 'true vocal cords' are distinguished from the 'false vocal folds', known as vestibular folds or ventricular folds, which sit slightly superior to the more delicate true folds. These have a minimal role in normal phonation, but can produce deep sonorous tones, screams and growls. The length of the vocal fold at birth is approximately six to eight millimeters and grows to its adult length of eight to sixteen millimeters by adolescence. DHT, an androgen metabolite of testosterone which is secreted by the gonads, causes changes in the cartilages and musculature of the larynx when present in high enough concentrations, such as during an adolescent boy's puberty: The thyroid prominence appears, the vocal folds lengthen and become rounded, and the epithelium thickens with the formation of three distinct layers in the lamina propria.. These changes are only partially reversible via reconstructive surgery such as chondrolaryngoplasty, feminization laryngoplasty, and laser tuning of the vocal cords.

=== Pharmacokinetics === Flunarizine is well absorbed (>80%) from the gut and reaches maximal blood plasma concentrations after two to four hours, with more than 99% of the substance bound to plasma proteins. It readily passes the blood–brain barrier. When given daily, a steady state is reached after five to eight weeks. Concentrations in the brain are about ten times higher than in the plasma. It is metabolised in the liver, mainly by the enzyme CYP2D6. At least 15 different metabolites are described, including (in animals) N-desalkyl and hydroxy derivatives and glucuronides. Less than 1% is excreted in unchanged form, and the main excretion path is via bile and faeces. Elimination half life varies widely between individuals and is about 5 to 15 hours after a single dose, and 18 to 19 days on average when given daily.

=== Advancing women in academia === Masur aims to advance and increase the visibility of women in STEMM. She uses her voice to create opportunities for women in science and fights for more equitable academic space. During her tenure at Mount Sinai, Masur was the first Dean of Faculty Developmencreating mentorship opportunities for women and men . She is a member of the Office of Gender Equity as Director of the Office for Women's Careers, which evolved from the Women Faculty Group at Mount Sinai (established in 1986). As the Director of the Office of Women's Careers, she advocates for women at ISMMS. Targeted programs and monthly events are hosted for women to discuss juggling career with family and to provides them with mentorship and leadership opportunities. Masur has published works describing the development of Women in Cell Biology (WICB) as well as anticipations of the future of women in STEMM. Masur held leadership roles including Chair of Diversity Issues Committee on Women and Minorities for the Association for Research in Vision and Ophthalmology from 1997 to 1999, co-director of the National Eye Institute's "Fundamental Issues in Vision Research" at the Marine Biological Laboratory from 2001 to 2010, and Chair of Women in Cell Biology for the American Society of Cell Biology from 2010 to 2016. In 2015 the American Society for Cell Biology honored Masur by naming one of their leadership awards the "Sandra K. Masur Senior Leadership Award" for efforts in scientific leadership and her long history of creating opportunities for women.

A 2014 study of 18 Latin American countries in the 20th-century study found the legislative powers of the presidency does not influence coup frequency. A 2019 study found that when a country's politics is polarized and electoral competition is low, civilian-recruited coups become more likely. A 2023 study found that civilian elites are more likely to be associated with instigating military coups while civilians embedded in social networks are more likely to be associated with consolidating military coups.

Although no approved therapeutics are based on ricin, it does have the potential to be used in the treatment of tumors to destroy targeted cells. Because ricin is a protein, it can be linked to a monoclonal antibody to target cancerous cells recognized by the antibody. The major problem with ricin is that its native internalization sequences are distributed throughout the protein. If any of these native internalization sequences are present in a therapeutic agent, the drug will be internalized by, and kill, untargeted non-tumorous cells as well as targeted cancerous cells. Modifying ricin may sufficiently lessen the likelihood that the ricin component of these immunotoxins will cause the wrong cells to internalize it, while still retaining its cell-killing activity when it is internalized by the targeted cells. However, bacterial toxins, such as diphtheria toxin, which is used in denileukin diftitox, an FDA-approved treatment for leukemia and lymphoma, have proven to be more practical. A promising approach for ricin is to use the non-toxic B subunit (a lectin) as a vehicle for delivering antigens into cells, thus greatly increasing their immunogenicity. Use of ricin as an adjuvant has potential implications for developing mucosal vaccines.

Sources: en.wikipedia.org

Reference notes

=== Research === The molecular mechanisms of chemical toxicity, carcinogen metabolism, and inter-individual genetic variability are the main subjects of Eaton's scientific research. His early research focused on the bioactivation and detoxification pathways of Aflatoxin B1, describing species variations in Cytochrome P450 enzymes (specifically CYP1A2 and CYP3A4) and Glutathione S-transferases (GSTs) to clarify human cancer risks. Additionally, he studied glutathione production and GST-mediated detoxification of pesticides, contaminants, and medicinal substances in Phase II biotransformation. Later in his career, Eaton co-authored studies on the use of "organ-on-a-chip" microphysiological systems, such as dual liver-kidney platforms, to assess the toxicity of nanoparticles and organ damage brought on by substances like aristolochic acid.

Dickey, Eddy's private secretary for the last three years of her life, wrote that hour-long watches were held in her home three times a day to protect her against it. The Manual of the Mother Church forbids members from practising it, and requires that Christian Science teachers instruct students "how to defend themselves against mental malpractice, and never to return evil for evil".

The Latam Pulse survey, carried out by Atlasintel and released on 11 February, showed that President Lula had 45.9% approval and 51.4% disapproval, the worst mark in the historical series. Rejection is higher among men, young people aged 16 to 44, evangelicals, and residents of the Central-West, North, South, and Southeast regions. In the Northeast, the rates are balanced. The overall evaluation of the government also worsened, with 46.5% considering the administration bad or terrible. Concern about the economy doubled, being cited by 29% of Brazilians, behind only crime (58%) and corruption (49%). Inflation is the biggest economic problem, mentioned by 75% of respondents. On tax reform, 41.5% considered it progress in need of improvement, 23% saw it as progress, and 35% classified it as a setback. The Datafolha survey, released by Folha de S.Paulo on 14 February, points to a fall in President Lula's approval, recording the lowest rate of his three terms. According to the survey, 24% of respondents rated the government as excellent or good, while 41% considered it bad or terrible. Another 32% classified the administration as regular, and 2% did not know how to respond. Compared with the previous survey, carried out in December 2024, approval fell from 35% to 24%, while disapproval increased from 34% to 41%. The fall was observed in different segments. Among voters with income of up to two minimum wages, approval fell from 44% to 29%. Among those earning more than ten minimum wages, it went from 32% to 18%.

Acetoxolutamide is a nonsteroidal androgen and selective androgen receptor modulator (SARM) which was described in 2000 and was never developed or marketed for medical use. It was derived from structural modification of the nonsteroidal antiandrogen bicalutamide and the nonsteroidal SARM acetothiolutamide. Acetoxolutamide shows greatly improved pharmacokinetic properties and anabolic and androgenic potency relative to acetothiolutamide in animals. It is the (2R) enantiomer of andarine (also known as acetamidoxolutamide or androxolutamide).

Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics.

Sources: en.wikipedia.org

Frequently asked questions

What is the main molecular target of cardarine?

It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.

Why did development of GW501516 stop?

Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.

Does cardarine improve endurance in people?

Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Network